ArticleNeurourology and urodynamics2026
Evaluating Outcomes of Sacral Neuromodulation in Patients With Multiple Sclerosis.
Article in Neurourology and urodynamics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the revision and removal rates of sacral neuromodulation (SNM) in patients with multiple sclerosis (MS) using a large national administrative dataset.
methodsThis was a retrospective cohort study using the Premier Healthcare Database. There were 13 913 patients analyzed between the years of 2006 and 2022), 218 of whom had diagnosis of MS. Patients were categorized into two groups as with MS and without any neurological disorders including MS (controls). The primary outcome was the relationship of MS on the 1- and 5-year device revision/removal rates. Secondary outcomes were associated complication rates within 1 year and beyond 1 year, the association between type of antibiotic prophylaxis and infectious complications.
resultsPatients with MS had similarly low rates of mechanical (within 1 year 1.8% vs. 2.1%; p = 0.98, and beyond 1 year 2.8% vs. 4.5%; p = 0.28), infectious (within 1 year 1.4% vs. 0.84%; p = 0.62, and beyond 1 year 0% vs. 0.29%; p = 0.88), and other complications (within 1 year 0.46% vs. 0.73%; p = 0.95, and beyond 1 year 0.46% vs. 0.93%; p = 0.71) within and beyond 1 year compared to controls, respectively. There was no statistically significant difference in revision/removal rates at 1 and 5 years between MS (11.2% and 29.9%) and for control patients (8.1% and 26.9%), respectively. In multivariable Cox proportional hazards models, MS was not found to be associated with removal/revision.
conclusionOur results suggest that a diagnosis of MS does not appear to impact SNM associated revision/removal rates and is associated with similarly low rates of complications compared to patients without any neurologic condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.